Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Bought by Granahan Investment Management LLC

Granahan Investment Management LLC boosted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 69.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 227,397 shares of the company's stock after buying an additional 93,259 shares during the period. Granahan Investment Management LLC owned 0.11% of Cellebrite DI worth $5,010,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in shares of Cellebrite DI by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock worth $7,202,000 after buying an additional 75,092 shares during the period. Harbor Capital Advisors Inc. increased its position in shares of Cellebrite DI by 65.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company's stock worth $3,473,000 after purchasing an additional 62,320 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Cellebrite DI during the fourth quarter valued at about $9,995,000. Teacher Retirement System of Texas purchased a new stake in shares of Cellebrite DI during the fourth quarter valued at $442,000. Finally, New York State Common Retirement Fund lifted its holdings in shares of Cellebrite DI by 2.6% during the fourth quarter. New York State Common Retirement Fund now owns 189,599 shares of the company's stock worth $4,177,000 after purchasing an additional 4,838 shares during the period. Hedge funds and other institutional investors own 45.88% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on CLBT shares. Lake Street Capital boosted their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. JPMorgan Chase & Co. lowered their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday. Finally, Needham & Company LLC dropped their target price on shares of Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $22.43.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT traded up $0.17 during trading on Friday, hitting $17.44. 872,668 shares of the company were exchanged, compared to its average volume of 1,450,780. The firm's 50 day moving average price is $19.02 and its 200-day moving average price is $20.24. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30. The stock has a market capitalization of $4.18 billion, a P/E ratio of -12.54, a PEG ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, equities research analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.